FIELD: biotechnology.
SUBSTANCE: disclosed are antibody molecules which bind mesothelin (MSLN) and CD137, as well as a pharmaceutical composition comprising them. Said antibody molecules contain a CDR-based binding site for MSLN and an antigen-binding site for CD137 located in the constant domain of the antibody molecule. Invention also relates to nucleic acids coding antibodies, expression vectors and host cells containing said nucleic acids, a method of producing the antibody.
EFFECT: invention provides higher binding affinity of antibody molecule with immobilized MSLN than with MSLN in solution, and can find application in cancer treatment.
29 cl, 14 dwg, 26 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| ANTIBODIES TARGETING BONE | 2018 |
|
RU2801206C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| ANTICANCER VACCINES | 2017 |
|
RU2718663C2 |
